Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
5 Market outlook Eli Lillys oral non-peptide GLP-1RA orforglipron is advancing through the ACHIEVE Phase III program, with Lilly signaling regulatory submissions for obesity in 2025 and type 2 diabetes in 2026, following positive results from both Phase 2 obesity (GZGI) and Phase 3 T2DM (ACHIEVE-1) trials
High heterogeneity was noted (I 2 of 75.1%)
W.ZhangY
)
Results BPA exposure induced significant hepatorenal toxicity, characterized by elevated transaminases, impaired renal function, and electrolyte imbalance
US$ 24.90
US$ 29.43
US$ 20.97
US$ 20.11
US$ 28.82
